Skip to search formSkip to main contentSkip to account menu

XL147

Known as: PI3K Family Kinase Inhibitor XL147 
An orally bioavailable small molecule, targeting the class I phosphatidylinositol 3 kinase (PI3K) family of lipid kinases, with potential… 
National Institutes of Health

Related topics

Related topics

4 relations
NCIt Antineoplastic Agent TerminologySAR245408

Broader (2)

QuinoxalinesSulfonamides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Cellular Metabolic Heterogeneity In Vivo Is Recapitulated in Tumor Organoids1
2015
2015
Dual PI3K/mTOR inhibitor, XL765 (SAR245409), shows superior effects to sole PI3K [XL147 (SAR245408)] or mTOR [rapamycin] inhibition in prostate cancer cell models
Deregulation of phosphatidylinositol-3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) signaling… 
2015
2015
The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
Dysregulation of PI3K/PTEN pathway components, resulting in hyperactivated PI3K signaling, is frequently observed in various… 
Highly Cited
2013
Highly Cited
2013
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors
Purpose: SAR245408 is a pan-class I phosphoinositide 3-kinase (PI3K) inhibitor. This phase I study determined the maximum… 
Highly Cited
2013
Highly Cited
2013
Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors.
The antibody trastuzumab is approved for treatment of patients with HER2 (ERBB2)-overexpressing breast cancer. A significant… 
2013
2013
Initial testing (stage 1) of the phosphatidylinositol 3′ kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program
Activation of the PI3 kinase pathway occurs frequently in many adult cancers and is implicated in tumor cell proliferation… 
2012
2012
Progress in breast cancer research
Breast cancer is a heterogeneous disease composed of multiple different subtypes with distinct molecular features and clinical… 
Review
2010
Review
2010
Colorectal cancer molecular biology moves into clinical practice
The promise of personalised medicine is now a clinical reality, with colorectal cancer genetics at the forefront of this next… 
2010
2010
A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced solid tumors.
3078 Background: Upregulation of PI3K pathway signaling is associated with tumor resistance to P and C. The oral selective Class… 
2009
2009
Phase I dose-escalation study of XL147, a PI3K inhibitor administered orally to patients with solid tumors.
3500 Background: XL147 is a selective inhibitor of Class I PI3K isoforms. In preclinical cancer models XL147 is cytostatic or… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)